Confirming previously reported data, BRAF and NRAS mutations were mutually exclusive in our patients' collection; overall, BRAF or NRAS mutations were detected in 23/34 (68%) primary tumours and 24/35 (69%) lymph node metastases from the same melanoma patients (Table 5). This evidence concerns the gene BRAF and melanoma.